SCHEMBL17100770

SCHEMBL17100770

COc1ccc(-c2noc(N3CCN(Cc4ccc5c(c4)OCO5)CC3)n2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.64
MAPT P10636 9/20 0.57
ALDH1A1 P00352 6/20 0.57
KDM4E B2RXH2 5/20 0.57
HPGD P15428 4/20 0.57
NPC1 O15118 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
RAB9A P51151 1/20 0.57
TSHR P16473 3/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
LMNA P02545 3/20 0.53
HTT P42858 5/20 0.52
TP53 P04637 2/20 0.52
MCHR1 Q99705 1/20 0.52
MAPK1 P28482 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HSD17B10 Q99714 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
CYP1A2 P05177 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100594 0.90 MAPT (0.58) POLBMAPTALDH1A1KDM4EHPGD
SCHEMBL17100837 0.89 MAPT (0.56) POLBMAPTALDH1A1SMN1; SMN2TSHR
SCHEMBL17100737 0.89 ALDH1A1 (0.55) POLBMAPTALDH1A1KDM4EHPGD
SCHEMBL17100584 0.87 KDM4E (0.58) POLBMAPTALDH1A1KDM4ENPC1
SCHEMBL17100655 0.82 MAPT (0.66) MAPTALDH1A1KDM4ENPC1SMN1; SMN2
SCHEMBL17100869 0.81 LMNA (0.56) POLBMAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL11518394 0.80 MEN1 (0.58) POLBALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL17100766 0.77 KDM4E (0.63) POLBALDH1A1KDM4ESMN1; SMN2TSHR
SCHEMBL17100663 0.76 MAPT (0.55) MAPTKDM4ENPC1SMN1; SMN2TSHR
SCHEMBL19300110 0.75 CYP1A2 (0.70) POLBMAPTALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US claimed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP claimed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT POLB 2985/4885MAPT 3/4885ALDH1A1 482/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT POLB 2935/4885MAPT 3/4885ALDH1A1 561/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT POLB 2985/4885MAPT 3/4885ALDH1A1 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.